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 The conformational state of hERG1 channels
determines integrin association, downstream signaling,
and cancer progression
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Ion channels regulate cell proliferation, differentiation, and migration in normal and neoplastic cells through cell-cell
and cell–extracellular matrix (ECM) transmembrane receptors called integrins. K+ flux through the human ether-à-go-
go–related gene 1 (hERG1) channel shapes action potential firing in excitable cells such as cardiomyocytes. Its abun-
dance is often aberrantly high in tumors, where it modulates integrin-mediated signaling. We found that hERG1
interacted with the b1 integrin subunit at the plasma membrane of human cancer cells. This interaction was not de-
tected in cardiomyocytes because of the presence of the hERG1 auxiliary subunit KCNE1 (potassium voltage-gated
channel subfamily E regulatory subunit 1), which blocked the b1 integrin–hERG1 interaction. Although open hERG1
channels didnot interact as stronglywithb1 integrins asdid closed channels, current flow throughhERG1channelswas
necessary to activate the integrin-dependent phosphorylation of Tyr397 in focal adhesion kinase (FAK) in both normal
and cancer cells. In immunodeficientmice, proliferationwas inhibited in breast cancer cells expressing forms of hERG1
with impaired K+ flow, whereas metastasis of breast cancer cells was reduced when the hERG1/b1 integrin interaction
was disrupted. We conclude that the interaction of b1 integrins with hERG1 channels in cancer cells stimulated dis-
tinct signaling pathways that depended on the conformational state of hERG1 and affected different aspects of
tumor progression. e.sc o
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Cell adhesion to the extracellular matrix (ECM) is critical to various
processes, including cell migration and synaptic plasticity, and the de-
cision between proliferation and differentiation (1, 2). Both voltage- and
ligand-gated ion channels regulate how cells respond to the ECM by
interacting with integrin receptors (3, 4). Integrin receptors are trans-
membrane proteins consisting of various a and b subunits. Inmammals,
they can form more than 20 different heterodimers with specific ECM
binding patterns (5, 6).Under resting conditions, integrin receptors reside
in a folded low-affinity conformational state. Upon activation by extra-
cellular or intracellular ligands or binding partners, they shift to a high-
affinity extended conformation (7, 8), which mediates both “outside-in”
and “inside-out” signaling (5). An important early signal triggered by in-
tegrin engagement is the phosphorylationof focal adhesion kinase (FAK),
which, in turn, regulates downstream signaling (9).A common molecular partner of integrin receptors is the human
ether-à-go-go–related gene 1 protein (hERG1, also known as Kv11.1).
In cardiomyocytes, hERG1mediates the cardiac repolarizing current Ikr
(10) in associationwith accessory subunits such as the potassiumvoltage-
gated channel subfamily E regulatory subunit 1 (KCNE1, also known as
MinK1). Moreover, hERG1 regulates excitability in the central nervous
system, endocrine cells, and smooth muscle (11, 12). However, infor-
mation about the interaction between integrin receptors and hERG1 is
available only for neoplastic cells. The abundance of hERG1 is often
aberrantly high in human cancers, and this channel is implicated in dif-
ferent stages of neoplastic progression, such as cell proliferation and sur-
vival, invasiveness, and neoangiogenesis (12–14). Because these processes
are regulated by cell adhesion to the ECM, the cross-talk between integrin
receptors and hERG1may constitute a unifyingmodulatory mechanism
of the cellular response to the microenvironment in both normal and
tumor tissue (4, 15).
Integrin receptors and ion channels communicate by diffusible
signals (16–20) as well as by forming macromolecular complexes
(21–25). In particular, the b1 integrin–mediated adhesion to fibronectin
activates hERG1 currents (IhERG1) in different cell types (17, 26). In neu-
roblastoma cells, this process is mediated by Gai protein (17) and trig-
gers integrin-dependent signaling cascades (23, 26). In addition, cell
adhesion to fibronectin generally stimulates the formation of a macro-
molecular complex between hERG1 and b1 integrin (hERG1/b1 integrin
complex) (23), which may recruit growth factor receptors such as vas-
cular endothelial growth factor receptor–1 (27) and CXCR-4 (28).
Therefore, hERG1 takes part in multiprotein complexes that constitute
major signaling centers in different cell types.
How hERG1 and b1 integrin interact and how the ensuing macro-
molecular complex responds to diffusible signals is unknown. The role1 of 13
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hERG1-related signals is also unclear. Here,
we first investigated why the hERG1/b1 in-
tegrin complex was formed in cancer cells
but not in heart tissue, where hERG1 is
found with its ancillary subunits (11). Next,
we studied themechanismof the interaction
of the two proteins using deletion mutants.
The protein-protein interaction was further
confirmed with Förster resonance energy
transfer (FRET) analysis (29–32). Using
hERG1 mutants with alterations in either
conductance or gating, we sought to dis-
criminate between the contributions of the
channel’s conformational state and K+ flow
to the assembly of the macromolecular
complex and to downstream signaling. Fi-
nally, we studied the in vivo effects of dis-
rupting the interaction between hERG1
and b1 integrin on the growth andmetasta-
sis of breast cancer cells xenografted inmice. o
n
 A
pril 5, 2017
http://stke.sciencem
ag.org/
ed from
 RESULTSKCNE1 and b1 integrin compete for
binding to hERG1
We compared the interaction between
hERG1 and b1 integrin in primary cancer
samples and surgical samples from human
hearts.b1 integrin immunoprecipitates from
colorectal cancers (CRCs), pancreatic
cancers (PCs), acute myeloid leukemia
(AML), and chronic myeloid leukemia
(CML) contained a hERG1 band (Fig. 1A,
left). Conversely, a b1 integrin band was de-
tected in hERG1 immunoprecipitates from
CRC, PC, and CML-1 samples (Fig. 1A,
right). In contrast, no association between
hERG1 and b1 integrin was detected in car-
diac tissue from human atria (Fig. 1B). Be-
cause hERG1 associates with KCNE1 in
cardiomyocytes (10, 33), we hypothesized
that the ancillary protein could impair the
channel interaction with b1 integrin. We
first verified that bothhERG1 (Fig. 1B, input
hERG1) andKCNE1 (Fig. 1C)were present
in the heart samples. In contrast, neither the
KCNE1 transcript nor the corresponding
protein was found in the tumor cell lines
with a hERG1/b1 integrin complex (Fig.
1C) (26, 27). Next, we expressed KCNE1
in HCT116 cells, which have endogenous
hERG1, or in human embryonic kidney
(HEK) 293 cells, which lack the potassium
channel and were transfected with hERG1.
The presence of transcript for KCNE1 was
verified by quantitative real-time polymer-
ase chain reaction (QPCR) (fig. S1, A and
B). In HEK cells plated on fibronectin, theA
B
C
D E
Fig. 1. hERG1 and b1 integrin associate in human cancer tissue but not in cardiac tissue. (A) Left: Coimmunopreci-
pitation of b1 and hERG1 from CRC, PC, AML, and CML samples. Right: Coimmunoprecipitation of hERG1 and b1 from CRC,
PC, and one CML sample. Bottom: Western blots (WBs) of total lysates (input) from the same tumor samples for hERG1 or
b1 integrin (b1). Representative of three independent experiments.mAb,monoclonal antibody. (B) Coimmunoprecipitation
of b1 and hERG1 (left) and coimmunoprecipitation of hERG1 and b1 in human heart atria. Representative of at least three
independent experiments. Differences in the molecular masses of hERG1 bands in the various cancer tissues are due to
differential posttranslational processing (56, 57). (C) Left: QPCR of KCNE1 and GAPDH in a representative heart sample, two
CRC cell lines (HCT8 andHCT116), andoneAML cell line (FLG29.1). Lane 1: 100–base pair (bp) standard (St); lane 2: negative
control (Neg. control). Representative of three independent experiments. Right: Western blot of total protein lysates from
the same samples for KCNE1 and tubulin. (D and E) Coimmunoprecipitation of b1 and hERG1 fromHEK cells (D) or HCT116
cells (E) transfected or not with KCNE1. a.u., arbitrary units. Representative of three independent experiments performed in
each cell line; the corresponding densitometric results are given in the bar graph. P values were calculated with respect to
HEK-hERG1 and HCT116-wild type (WT) cells, respectively; Student’s t test.2 of 13
SC I ENCE S I GNAL ING | R E S EARCH ART I C L Eformation of the hERG1/b1 integrin complex was inhibited by KCNE1
(Fig. 1D). Similar results were obtained in HCT116 cells (Fig. 1E), al-
though the effect was smaller. These results suggested that KCNE1 and
b1 integrin competed for binding to hERG1, which could explainwhy for-
mation of the hERG1/b1 integrin complex occurs only in neoplastic tissue.Becchetti et al., Sci. Signal. 10, eaaf3236 (2017) 4 April 2017hERG1 and b1 integrin may directly physically interact
To study how hERG1 and b1 integrin assemble, we usedHEK cells trans-
fected with wild-type (HEK-hERG1) or mutant hERG1 complementary
DNA (cDNA). Endogenous b1 integrin is present in these cells and coim-
munoprecipitated with hERG1 in cells allowed to adhere to fibronectin o
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Fig. 2. FRET shows close interaction of hERG1 and b1 integrin on the plasma membrane. (A) Left: Image in false colors corresponding to the tm shown in the lifetime
histogramandemission spectra (black curve) for a cell showing FRET. These spectra are compared to themeasuredemission spectra for eCFP (cyan curve) and eYFP (yellow curve).
Right: Image in false colors and related histogram corresponding to fast lifetime values tf (left) and to slow lifetime values ts (right) for the same cell. Images are representative of
four independent experiments, in which 104 total cells were analyzed. (B) FRET measurements, expressed as donor mean lifetimes carried out on HEK-hERG1 cells seeded onto
fibronectin (FN) (n = 14 cells, from three independent experiments) or BSA (n = 12 cells, from three independent experiments). P valuewas calculatedwith respect to cells seeded
onBSA; Student’s t test. (C) Examples of lifetime images for a cell on fibronectin not showing FRET (top left), for a cell on fibronectin showing FRET (bottom left), for a cell on BSAnot
showing FRET (top right), and for a cell on BSA showing FRET (bottom right). (D) Representative raw images of donor (hERG1, left) and acceptor (b1, right) (before acceptor
photobleaching) at two different focal planes, namely, “Bottom plasma membrane” and “Z-slice plasma membrane” in HEK 293 cells. Scale bar, 10 mm. The intensity scale is
displayed in the top right corner of each image. Each image is representative of 12 total images per experimental condition (WT and mutants). (E) hERG1/b1 FRET efficiency
histograms of bottomplasmamembrane (black solid line) images (n=6 images, each sampling at least five cells obtained from twodifferent transfection experiments) and Z-slice
plasmamembrane (blue solid line) images (n=6 images, each sampling at least five cells obtained from twodifferent transfection experiments), filtered for b1 abundance (see the
Supplementary Materials on image processing protocol). Mean FRET efficiencies were 0.23 ± 0.05 (Bottom plasma membrane) and 0.24 ± 0.05 (Z-slice plasma membrane). The
underlying distributions were not statistically different [two-sample Kolmogorov-Smirnov (K-S) test].3 of 13
SC I ENCE S I GNAL ING | R E S EARCH ART I C L E(fig. S2) (23). To study whether the two proteins interacted directly, we
applied hyperspectral–fluorescence lifetime imagingmicroscopy–FRET
(HS-FLIM-FRET) (34) on HEK cells transfected with cyan fluorescent
protein (CFP)–labeled hERG1 and yellow fluorescent protein (YFP)–
labeled b1 integrin (fig. S3). The fluorescence decay was characterized
by biexponential behavior with one long-lived and one fast-decaying
component. From each cell (Fig. 2A), we obtained the lifetimes (tsBecchetti et al., Sci. Signal. 10, eaaf3236 (2017) 4 April 2017and tf, respectively) and fraction sizes (As and Af, respectively) of both
components for all pixels of the image (control experiments are shown
in figs. S4 and S5). The slow lifetime was similar to the lifetime of
enhanced CFP (eCFP) when no energy transfer occurred (ts = 2.48 ±
0.09 ns; see the SupplementaryMaterials). The fast lifetime is a signature
of energy transfer and the close proximity of hERG1 to b1 integrin. By
using eq. S2 (Supplementary Materials and Methods), the calculated o
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 FRET efficiency was 0.77 ± 0.04. We also
compared the HS-FLIM-FRET signals in
cells cultured in fibronectin or bovine ser-
um albumin (BSA). Measurements were
stopped at 100 min because after this time,
cells cultured inBSAprogressivelydetached
from the substrate. The donor mean
lifetime values (tm) were calculated using
eq. S3 (Supplementary Materials). For cells
cultured in fibronectin, tm was 1.71 ± 0.05,
whereas for cells cultured in BSA, tm was
2.00 ± 0.08 (Fig. 2B). Shorter lifetimes in
cells cultured in fibronectin indicated high-
er FRET efficiency in elongated cells that
strongly adhered to the substrate (Fig. 2C,
FRET). In contrast, longer lifetimes, which
indicated lower FRET efficiency or no
FRET, corresponded to round cells or cells
fixed to the substrate through small filopo-
dia (Fig. 2C, No FRET).
The hERG1/b1 integrin complex is
localized to the plasma membrane
Todemonstrate that hERG1andb1 integrin
interaction occurred at the plasma mem-
brane, the functional site of both proteins,
we performed FRET experiments by accep-
tor photobleaching imaging (29) on fixed
HEK cells. Donors and acceptors were
labeled using monoclonal antibodies
directed against hERG1, whichwas coupled
to Alexa Fluor 488, and against b1 integrin,
which was coupled to Alexa Fluor 546 (figs.
S6 and S7). Confocal imaging allowed us to
image FRET at various locations in the cell.
We chose two different focal planes, one lo-
cated at the plasma membrane close to
the fibronectin-coated substrate (Fig. 2D,
Bottom plasma membrane) and one lo-
cated at about half of the maximal cell
thickness (Fig. 2D, Z-slice plasma mem-
brane). Data analysis confirmed that the
FRET signal originated on, or was proximal
to, the plasmamembrane (acceptormask in
fig. S7B). The average FRET efficiencies
calculated for the bottom and the equatorial
(Z-slice) plasma membranes were similar
(Fig. 2E). Hence, the interaction between
hERG1 and b1 integrin was not restricted
to the membrane portions involved in
cell-substrate adhesion but also occurred
in membrane patches distant from theA
B
D C
E
Fig. 3. The cytoplasmic domains of hERG1 and b1 integrin are not necessary for the complex assembly. (A) hERG1
currents measured in HEK cells stably transfected with the indicated constructs. Representative of at least four cells per
transfection condition analyzed in three independent experiments. (B) Coimmunoprecipitation of hERG1 and b1 using
the indicated antibodies from HEK-hERG1–, HEK-hERG1D2-370–, and HEK-hERG1DC+RD–expressing cells. Representa-
tive of three independent experiments; the corresponding densitometric results are given in the bar graph. Not statis-
tically different, one-way analysis of variance (ANOVA). (C) Scheme of the b1 integrin constructs used in these experiments.
(D) Immunoprecipitation of hERG1 from GD25 cells coexpressing the YFP-tagged constructs and hERG1. Western blotting
was performed with the YFP antibody or the hERG1 polyclonal antibody. The arrow on the left of the top panel indicates
the bands of b1 and b1-extra (lanes 2 and 3). Lanes 4 and 5 show two immunoprecipitates of hERG1 from 0.5 or 1 mg of
protein from b1-cyto–transfected GD25 cells. Bands corresponding to b1-cyto at about 80 kDa were not detected (dotted,
two-headed arrow). The panel on the right shows Western blots using YFP antibody (input YFP) or hERG1 polyclonal
antibody (input hERG1) on the same total cellular lysates from GD25 cells cotransfected with the indicated b1 integrin
constructs and hERG1. In the top panel, the upper arrow indicates the expected molecular mass of YFP-conjugated b1 in-
tegrin and b1-extra (about 147 kDa). The lower arrow indicates the expectedmolecular mass of b1-cyto (about 80 kDa). All
data reported in (D) are representative of three independent experiments; the corresponding densitometric results are
given in the bar graph. P values for b1-cyto were calculated with respect to b1-extra–hERG1 and b1-hERG1 cells; one-way
ANOVA. (E) Coimmunoprecipitation of b1 and hERG1 from GD25-b1-TR cells, which stably express the b1-extra construct.
Blots are representative of two independent experiments.4 of 13
SC I ENCE S I GNAL ING | R E S EARCH ART I C L Eadhesion sites. The mean FRET efficiency for both locations was 0.24 ±
0.05, about fourfold smaller than the value measured by HS-FLIM-
FRET, which we attribute to the different labeling methods for hERG1
and b1 integrin.
Interaction between hERG1 and b1 integrin does not require
the hERG1 intracellular domains or the cytoplasmic
C-terminal domain of b1 integrin
To define the molecular domains implicated in the complex formation,
we performed electrophysiological analysis ofHEK cells stably expressing
forms of hERG1 lacking the entire N terminus (hERG1D2-370) or the C
terminus (hERGDC+RD) except for the amino acids from 1018 to 1122,
which constitute the recapitulation domain (RD) that allows hERG1
insertion into the plasmamembrane (35). As expected,whole-cell current
recordings indicated that hERG1D2-370 displayed the typical fast de-
activation conferred by N terminus deletion (36), whereas hERG1DC+RD
generally displayed current amplitudes considerably smaller than thoseBecchetti et al., Sci. Signal. 10, eaaf3236 (2017) 4 April 2017of hERG1 (Fig. 3A) (35). Immunoprecipitation analysis of these cells
suggested that the cytoplasmic hERG1 domains were dispensable for
assembly with b1 integrin (Fig. 3B). To test whether the intracellular
domain of b1 integrin interacted with hERG1, we transfected hERG1
and the following YFP-labeled constructs into GD25 cells, which are
deficient in b1 integrins (37): (i) full-length b1 integrin, (ii) b1 integrin
lacking theC terminus (b1-extra), and (iii) b1 integrinC terminus linked
to the transmembrane and extracellular portions of the interleukin-2
receptor (b1-cyto) (Fig. 3, C and D). Coimmunoprecipitation analysis
showed that hERG1coimmunoprecipitatedwith b1 integrin andb1-extra
but notwith b1-cyto (Fig. 3D), suggesting that the cytoplasmic domain of
b1 integrin was not necessary for interactionwith hERG1.We confirmed
this conclusion by performing coimmunoprecipitation using an anti-
body against b1 integrin in GD25-b1-TR cells, which stably express
b1 integrin lacking the C terminus (Fig. 3E). We concluded that the
cytoplasmic domains of hERG1 and b1 integrin were not necessary
for the interaction of these proteins. o
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 hERG1 gating, but not conduction,
regulates the complex formation
The results obtained with hERG1DC+RD
(Fig. 3, A and B) suggested that impairing
channel conduction did not affect the asso-
ciation of hERG1 with b1 integrin. To fur-
ther investigate this issue, we tested the
complex formation in the presence of
E4031, which blocks hERG1 (Fig. 4A) by
binding to the Phe656 residue that protrudes
into the channel pore (38). E4031 inhibited
the complex formation by about 80%
(Fig. 4B). This result could be explained
if K+ flux is critical for the complex forma-
tion or if the presence of E4031 locks a sub-
stantial fraction of the channels in the open
conformation, which may have a lower af-
finity for b1 integrin. To better distinguish
these mechanisms, we expressed several
mutant constructs in HEK cells: the non-
conducting hERG1-G628S (38), hERG1-
R531C, and hERG1-K525C, which are S4
domain mutants with altered activation
(39), and the noninactivating hERG1-
S620T (40). Flow cytometry analysis (41)
indicated that the plasma membrane abun-
dance of the mutants was ~25 to 30% less
compared to that of wild-type hERG1
(Fig. 4C). The strong decrease in K+ flow
for thehERG1-G628Smutant is not accom-
panied by gating alterations (38). hERG1-
G628S current amplitudeswere comparable
to thosedisplayedbyhERG1 in thepresence
ofE4031 (Fig. 4D).Cells expressinghERG1-
G628S had ameanmembrane voltage (Vm)
under resting conditions (Vrest) of −36.9 ±
1.9 mV, compared to −48.4 ± 2.3 mV in
cells expressing wild-type hERG1. Forma-
tion of the hERG1/b1 integrin complex
was not significantly impaired by hERG1-
G628S (Fig. 4E). Thus, although blockingA
D E
B
C
Fig. 4. Role of hERG1 current in the mac-
romolecular complex formation and sur-
face expression of WT and mutant hERG1
proteins. (A) Effect of E4031onwhole-cellWT
hERG1 currents in HEK-hERG1 cells. Current
traces show the blocking effect on tail cur-
rents at −120 mV. Bars give the average
hERG1 peak current densities in the presence
or absence of 2 mME4031 (n=5 cells analyzed
in three independent experiments). P value
was calculated with respect to hERG1 cells;
Student’s t test. (B) Coimmunoprecipitation
of b1 and hERG1 from HEK-hERG1 cells
seeded onto fibronectin, in the absence or
presence of 40 mM E4031. Representative of
three independent experiments; the
corresponding densitometric results are giv-
en in the bar graph. P value was calculated
with respect to hERG1 cells; Student’s t test.
(C) Membrane abundance of the indicated hERG1 constructs measured in HEK cells by flow cytometry and expressed
as mean fluorescence intensity (MFI). The mean fluorescence intensity of mock-transfected HEK cells was set as 1. Repre-
sentative of four independent experiments. Not statistically different, Kruskal-Wallis ANOVA with Dwass, Steel, Critchlow-
Fligner (DSCF)’s post hocmethod. (D) Whole-cell hERG1 currents in HEK-hERG1 cells (upper traces) and HEK-hERG1 G628S
cells (lower traces). Only the tail current at−120mV is shown (conditioning potentials are given inMaterials andMethods).
Currents were measured in the presence of 40 mM extracellular K+. Bars give the corresponding average peak current
densities for hERG1 andhERG1-G628S (n=8 cells analyzed in three independent experiments). P valuewas calculatedwith
respect to hERG1cells; Student’s t test. (E) Coimmunoprecipitationofb1 andhERG1fromHEK-hERG1andHEK-hERG1G628S
cells seeded onto fibronectin. Representative of five independent experiments; the corresponding densitometric results
are given in the bar graph. Not statistically different, Student’s t test.5 of 13
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 channel conduction with E4031 impaired
the complex assembly, data obtained with
the nonconducting hERG1-G628S mu-
tant suggested that decreased current flow
per se was not the main determinant of
the effect, in agreement with the results
obtained with hERG1DC+RD.
To test the alternative hypothesis that
the complex formation is sensitive to the
channel’s conformational state, we used
mutants with different steady-state activa-
tion properties (Fig. 5A). Similar to wild-
type hERG1, the hERG1-K525C protein
was detected at the plasma membrane
(Fig. 4C), although the maximal current
density was lower (Fig. 5B) and the activa-
tion curvewas shifted to amorenegativeVm
value (Fig. 5C). In agreement with previous
work (39), the estimated V1/2 of activation
wasaround−50mV,and themeasuredVrest
was −59.1 ± 1.1 mV. Hence, at steady state,
hERG1-K525C channels spend more time
in the open state than wild-type hERG1.
hERG1-R531C had a similar maximal cur-
rent density to that displayed by wild-type
hERG1 (Fig. 5B). The estimated V1/2 of ac-
tivation was about +35 mV (Fig. 5C). The
corresponding Vrest was −42 ± 2.6 mV,
implying that a large fraction of the hERG1-
R531C channels resided in the closed state in
our cells. Coimmunoprecipitation analysis
showed that less b1 integrin associated with
hERG1-K525C than with wild-type hERG1
or hERG1-R531C (Fig. 5D). This result sug-
gested that increasing the probability of the
channel being in the open state decreased
the complex formation. To further test this
hypothesis, we used the noninactivating
hERG1-S620T mutant, in which the open-
closed transition is not complicated by the
presence of the inactive state (40). Consistent
with the absence of inactivation (Fig. 5A),
hERG1-S620T had amaximal current densi-
ty of 447 ± 89 pA/pF (Fig. 5B), considerably
higher than that measured for wild-type
hERG1, and the measured Vrest was −59 ±
2.3 mV. Similarly to hERG1-K525C, the
complex association of hERG1-S620T with
b1 integrin was impaired compared to wild-
type hERG1 (Fig. 5E). These results are
consistent with the hypothesis that assembly
of the hERG1/b1 integrin complex was
hindered when the probability of the channel
transition toward the open state increased.
Thismechanismwas further investigated
by FRET experiments in an acceptor photo-
bleaching setting, onHEKcells expressing ei-
ther wild-type hERG1, hERG1-R531C,
or hERG1-K525C. The FRET efficiencyA B
C
D E
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Fig. 5. hERG1 gating regulates the hERG1/b1 complex formation. (A) Typical whole-cell current traces elicited in HEK
cells stably transfected with either hERG1-K525C, hERG1-R531C, or hERG1-S620T. Representative of at least five cells per
transfection condition analyzed in three independent experiments. (B) Comparison of the maximal current densities of
hERG1-, hERG1-K525C–, hERG1-R531C–, and hERG1-S620T–expressing HEK cells. Data are average peak tail current den-
sities calculated fromat least five cells per transfection condition analyzed in three independent experiments, at test pulses
of +40, +50, +70, and +60mV for hERG1, hERG1-K525C, and hERG1-R531C. P valueswere calculatedwith respect to hERG1
or hERG1-R531C cells; Kruskal-Wallis ANOVAwithDSCF’s post hocmethod. (C) Activation curves of hERG1-, hERG1-K525C–,
and hERG1-R531C–expressing HEK cells. Data points are normalized peak tail currents calculated from experiments as in
(A). (D) Coimmunoprecipitation of b1 and hERG1 from HEK 293 cells expressing hERG1, hERG1-K525C, and hERG1-R531C
seeded onto fibronectin. Representative of three independent experiments; the corresponding densitometric results are
given in the bar graph. P values were calculated with respect to hERG1 cells; one-way ANOVA. (E) Same as (D) but for
hERG1-S620T. Representative of three independent experiments; the corresponding densitometric results are given in
the bar graph. P value was calculated with respect to hERG1 cells; Student’s t test with Welch correction. (F) Probability
distributions of FRET efficiency from confocal images of cells expressing b1 integrin and hERG1, hERG1-R531C, or hERG1-
K525C (n = 6 images, each sampling at least five cells obtained from two different transfection experiments), filtered for
b1 abundance (see the Supplementary Materials for details on image processing). Mean FRET values are 0.24 ± 0.06, 0.23 ±
0.06, and 0.24± 0.06 for hERG1, hERG1-R531C, and hERG1-K525C, respectively. No statistical differencewas foundbetween
all the distribution couples, as tested by two-sample K-S test (P > 0.05). (G) Percentage of FRET events for hERG1, hERG1-
R531C, and hERG1-K525C (assessing complex formation between hERG1 and b1). P value was calculated with respect to
hERG1 cells; one-way ANOVA with Hochberg’s (GT2) post hoc method.6 of 13
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 distributions for the three conditions were not statistically different (Fig.
5F), demonstrating that energy transfer took place in both hERG1-
R531C– and hERG1-K525C–transfected cells. This finding suggested
that the hERG1/b1 integrin complex, once it was formed, was structurally
similar in wild-type and mutant channels. Next, we determined the per-
centage of FRET events, which reflected the abundance of hERG1/b1 in-
tegrin complexes. In agreement with the coimmunoprecipitation data,
the complex formation was significantly impaired in cells expressing
hERG1-K525C (Fig. 5G). These findings did not depend on the relative
ratio between donor (hERG1) and acceptor (b1 integrin) present in the
membrane (fig. S8).
hERG1 current flow regulates FAK phosphorylation and cell
proliferation in vivo
We have previously shown that the b1 integrin–dependent FAK phos-
phorylation in HEK cells expressing wild-type hERG1 relies on hERG1
activation (23). Hence, we studied how this process was modified by
either E4031 or mutant channels. FAK was immunoprecipitated from
HEK cells expressing wild-type hERG1 (treated or not treated with
E4031) or one of the mutant hERG1 channels (Fig. 6A). The phospho-
rylation of Tyr397 in FAK (23) was impaired in cells expressing mutant
hERG1 channels, with the exception of hERG1-S620T, compared to
that in HEK cells expressing wild-type hERG1 (Fig. 6A). This finding
suggests that the integrin-dependent FAK autophosphorylation re-
quired physiological hERG1 current amplitudes, which was impaired
for different reasons by hERG1-G628S, E4031, hERG1-K525C, and
hERG1-R531C, but not by hERG1-S620T. Because FAK controls vari-
ous cellular functions, including cell survival and proliferation (42), by
activating numerous signaling pathways, we tested the effects of the
above treatments on in vivo cell growth. We subcutaneously injected
HEK cells expressing wild-type hERG1, hERG1-G628S, hERG1-
K525C, or hERG1-R531C into immunodeficient nude mice. In miceBecchetti et al., Sci. Signal. 10, eaaf3236 (2017) 4 April 2017that received cells expressing the different mutants or expressing
wild-type hERG1 in the presence of E4031, the growth of subcutaneous
masses was reduced compared to mice injected with HEK cells
expressing wild-type hERG1 (Fig. 6B).
Disrupting the hERG1/b1 integrin complex inhibits
metastasis of breast cancer cells
We next tested whether such hERG1-mediated cell signals were present
in cancer cells in which the abundance of hERG1 is abnormally high and
hERG1 forms a macromolecular complex with b1 integrin (26, 28). Spe-
cific hERG1 blockade with either Way 123,398 or E4031 impairs the
phosphorylationofTyr397 inFAK(23,26–28). This processwas also stud-
ied in MDA-MB-231 breast cancer cells. Because these cells have low
amounts of hERG1, we transfected our wild-type and mutant hERG1
constructs, which approximately doubled the membrane amount of
hERG1 channels (Fig. 7A). Once again, only hERG1-K525C strongly im-
paired the hERG1/b1 integrin complex formation (Fig. 7B), whereas both
hERG1-R531C and hERG1-K525C impaired the integrin-dependent
phosphorylation of Tyr397 in FAK (Fig. 7C). We concluded that the
signaling interaction between hERG1 and b1 integrin was similar in
HEK and cancer cells.
Finally, we studied the effects of disrupting the hERG1/b1 integrin
complex in vivo, using MDA-MB-231 breast cancer cells transfected
with either hERG1, hERG1-K525C, or hERG1-R531C. Cells were
injected into either the right or left fourth breast of severe combined
immunodeficient (SCID) mice. The number of breasts displaying tu-
mor masses, the median volume of the tumor masses, and the presence
of metastases in inguinal lymph nodes and lungs were determined
5 weeks after injection (Fig. 7D and fig. S9). Although the growth of
tumors formed fromMDA-MB-231 cells was not affected by over-
expression of either mutant, the percentage of mice with metastases
in either the inguinal lymph nodes or the lungs (Fig. 7, D and E) was o
n
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.org/significantly decreased when the cells ex-
pressed hERG1-K525C. The percentage
of metastatic area (Fig. 7F) and the num-
ber of metastatic clusters (Fig. 7G) were
decreased in mice injected with MDA-
MB-231 cells expressing hERG1-K525C,
compared to those injected with cells
expressing either wild-type hERG1 or
hERG1-R531C. These results suggested
that disrupting the hERG1/b1 complex
by overexpressing the hERG1-K525C
mutant impaired the metastatic process.DISCUSSION
We used coimmunoprecipitation exper-
iments and FRET imaging to examine
whether hERG1 and b1 integrin interacted
directly on the plasma membrane. HS-
FLIM-FRET showed an increase in the fast
lifetime component in cells seeded and
spread onto fibronectin. The high FRET ef-
ficiency suggests that the two proteins were
in close proximity, within the upper limit of
theCFP-YFPdynamic range of 7.3 nm(43).
Whether proximitywas caused by direct in-
teraction or through the participation ofA B
kDa-
kDa-
kDa-
kDa-
M
Fig. 6. Phosphorylationof Tyr397 inFAK is regulatedby
hERG1 current. (A) Phosphorylation (p) of Tyr397 in FAK in
HEK cells expressing the indicated hERG1 constructs and
treated or not treated with 40 mM E4031, measured after
cell seeding on fibronectin. Representative of four
independent experiments; the corresponding densitomet-
ric results are given in the bar graph. P values were
calculated with respect to hERG1 cells; one-way ANOVA.
hERG1-S620T versus hERG1 is not significant, Student’s ttest. (B) Volume of tumor masses obtained in nude mice after subcutaneous injection of HEK 293 cells expressing the
indicated hERG1 constructs. One group of mice injected with HEK-hERG1 cells was treated by intraperitoneal injection
of E4031. Data are relative to six tumor masses for group (three mice per group). P values were calculated with respect
to mice injected with hERG1 cells; one-way ANOVA.7 of 13
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 other proteins in a multiprotein complex cannot be distinguished. The
interactionwas increased by cell adhesion on fibronectin. FRET experiments
further demonstrated that hERG1 and b1 integrin interaction occurred only
at the plasma membrane and not in cytosolic compartments. Moreover,
coimmunoprecipitation experiments showed that hERG1 and b1 integrinBecchetti et al., Sci. Signal. 10, eaaf3236 (2017) 4 April 2017F
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cinteracted on the plasma membrane in a
manner that didnot require the cytoplasmic
domains of these proteins. Nevertheless, be-
cause the hERG1 C terminus regulates
channel gating, an indirect contribution to
the complex formation cannot be ruled
out. Although we did not provide evidence
excluding the fact that the two proteins in-
teract through their extracellular domains,
we favor the conclusion that the interaction
takes place largely through the trans-
membrane portions. First, it seems unlikely
that thehighly extendedopenconformation
of the activated integrin (44) would interactsubstantially with the very short extracellular domain of hERG1. Second,
the interaction between the transmembrane domains would seem more
consistent with the gating dependence of the complex formation and
the competition between b1 integrin and KCNE1. The transmembrane
domain of b1 integrin is a short a helix, which also undergoes profoundA
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(19–300) (33–300) (33–300)ig. 7. Effects of inhibiting hERG1 currents
nd hERG1/b1 complex formation on neoplas-
c progression. (A) Expression of the indicated
ERG1 constructs transfected in MDA-MB-231
ells, measured as in Fig. 4C. Bars show the aver-
ge hERG1 mean fluorescence intensity of three
dependent experiments. Not statistically differ-
nt, Kruskal-Wallis ANOVA with DSCF’s post hoc
ethod. (B) Coimmunoprecipitation of b1 and
ERG1 from MDA-MB-231 cells expressing the in-
icated hERG1 constructs seeded onto fibronectin.
epresentative of three independent experiments;
e corresponding densitometric results are given
the bar graph. P values were calculated with re-
pect to hERG1 and hERG1-R531C cells; one-way
NOVA. (C) Phosphorylation of Tyr397 in FAK in
DA-MB-231 cells expressing the indicated hERG1
onstructs. Representative of three independent
xperiments; the corresponding densitometric
sults are given in the bar graph. P values were
alculated with respect to hERG1 cells; one-way
NOVA. (D) Table summarizing quantitative data
btained from the breast orthotopic xenograft
odel. (E) Left (Necropsy): Images of lungs from
presentative animals in which MDA-MB-231 cells
xpressing the indicated hERG1 constructs were
rthotopically injected in the breast. Middle (Lung
&E): Lung sections labeled with H&E (hematoxy-
n and eosin) from the same animal as in the left
anels. Right: Magnified images and sections im-
unostained with an antibody against human
ajor histocompatibility complex I (hMHC I). Scale
ars, 100 mm. (F) Percentage of metastatic area
nd (G) number of metastatic clusters per micro-
copic field in the lungs of mice injected with
DA-MB-231 cells expressing the indicated hERG1
onstructs. Values are averages of measurements
btained in at least three different microscopic
elds in both mouse lungs in five mice for each
jected experimental group. P values were cal-
ulated with respect to hERG1 and hERG1-R531C
ells; one-way ANOVA.8 of 13
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 conformational changes upon integrin engagement (45), and could in-
teract with the hERG1 domains that constitute the voltage sensor (11).
Instead, we found that assembly of this macromolecular complex de-
pended on the channel’s conformational state. We derived this conclusion
by comparing the degree of the complex formation of wild-type and mu-
tant hERG1 channels. From the respective steady-state activation curves
(Fig. 5, A and C) (39, 40), hERG1 and hERG1-R531C should primarily
reside in the closed (deactivated) state, whereas hERG1-K525C and the
noninactivating hERG1-S620T should spend more time in the open state.
Because the latter twomutants associated poorly with b1 integrin, we con-
cluded that the complex formation was hindered when hERG1 was in the
open state. Consistent with this notion, we observed impairment of the
complex formation in the presence of E4031 (Fig. 4A), which occupies
the channel pore and thus maintains hERG1 in the open conformational
state (11).Our interpretation is consistentwith the results obtainedwith the
nonconducting hERG1-G628S mutant, which shows impaired current
flow but a greater ability to interact with b1 integrin than hERG1-
K525C, hERG1-S620T, or wild-type hERG1 inhibited by E4031.
On the other hand, most of the conditions we tested tended to block
the phosphorylation of Tyr397 in FAK (namely, autophosphorylation),
which we used as an early marker of integrin-dependent downstream
signaling. The commonoutcomeof our treatmentswas a decrease in cur-
rent flow through hERG1. E4031 blocked the channel pore; hERG1-
G628S had a very low intrinsic channel conductance; hERG1-R531C
had a very low open probability at the Vrest typical of our cells; hERG1-
K525C, although generally active atVrest, tended nonetheless to display a
lowerwhole-cell current amplitude thanwild-typehERG1.The exception
was hERG1-S620T, which generated a higher whole-cell current ampli-
tude than that of wild-type hERG1 (Fig. 5, A and B). Consistent with our
interpretation, phosphorylation of Tyr397 in FAK in cells expressing this
mutant was similar to that in cells expressing wild-type hERG1.
We showed that these mechanisms operated in cancer cells. Under
all conditions in which IhERG1 was impaired, in vivo tumor growth was
decreased, suggesting that channel activation regulated cell prolifera-
tion, possibly by controlling signaling pathways downstream of FAK
activation (42,46). In contrast, disrupting thehERG1/b1 integrin complex
impaired the metastatic process of breast cancer cells. Therefore, the mo-
lecular association between hERG1 and b1 integrin appears to modulate
the intracellular machinery related to cancer cell migration and invasive-
ness.Anotherbiologically relevant findingwas that thehERG1/b1 integrin
complex was not detected in cardiomyocytes, which suggests that the
complex could be specific to tumor tissue. This difference could be caused
by direct competition between b1 integrin and the hERG1 ancillary sub-
unit KCNE1 in cardiomyocytes (Fig. 1). The competition between
KCNE1 and b1 integrin for hERG1 binding suggests that integrins could
substitute for KCNE1 as a binding partner in certain tissues. Nonetheless,
current evidence does not exclude the possibility that KCNE1 also binds
to b1 integrin.
Our present working hypothesis is that b1 integrin–dependent cell
signaling leading to autophosphorylation of FAK is regulated by hERG1
activation and requires normal current flow through the ion channel,
whereas the membrane macromolecular complex tends to recruit
hERG1 channels residing in the nonconducting states. As suggested
by single-cell analysis (16, 17), hERG1 reaches maximal stimulation
within a fewminutes of cell adhesion onto fibronectin. It is possible that
hERG1 activation occurring early during cell adhesion has a role in sti-
mulating FAK phosphorylation and the ensuing signaling pathways,
whereas the late formation of themacromolecular complex progressive-
ly shifts the hERG1 channel population toward the nonconductingBecchetti et al., Sci. Signal. 10, eaaf3236 (2017) 4 April 2017state. This process would turn off the early signaling cascade and favor
late integrin-dependent cytoskeleton reorganization toward migration
and invasion (7, 8, 46). Hence, these results open the way for studies
aimed at developing hERG1-related pharmacological compounds tar-
geting different aspects of the neoplastic progression.MATERIALS AND METHODS
Chemicals and antibodies
Unless otherwise indicated, chemicals and antibodies were purchased
from Sigma-Aldrich. Cell lysis buffer for protein extraction was from
Cell Signaling Technology (#9803), and Protein A/G Plus-Agarose for
immunoprecipitation was from Santa Cruz Biotechnology (sc-2003).
The following antibodies were used for immunoprecipitation and
Western blots, at the indicated concentrations: mAb-hERG1 (DT-331,
Di.V.A.L. Toscana SRL): immunoprecipitation, 5 mg/mg protein; rabbit
polyclonal antibody against hERG1 C terminus (hERG1 CT pan–
polyclonal antibody; DT-552, Di.V.A.L. Toscana SRL):Western blot,
1:1000; rabbit polyclonal antibody against b1 integrin C terminus
(RM12, Immunological Sciences): Western blot, 1:1000; mAb-b1 (TS2/
16, BioLegend): immunoprecipitation, 5 mg/mg protein; rabbit poly-
clonal antibody against green fluorescent protein (GFP)/YFP (Ab290,
Abcam):Western blot, 1:1000; rabbit polyclonal antibody against total
FAK (SC-8312, Santa Cruz Biotechnology): immunoprecipitation,
1 mg/mg protein andWestern blot, 1:1000; rabbit monoclonal antibody
against total FAK (EP695Y, Abcam): immunoprecipitation, 6 mg/mg
protein and Western blot, 1:1000; rabbit polyclonal antibody against
pTyr397FAK (BioSource International): Western blot, 1:1000; mouse
monoclonal antibody against KCNE1 (Abcam): Western blot, 1:500;
rabbit polyclonal antibody against human MHC class I (H-300; sc-
25619, Santa Cruz Biotechnology): immunohistochemistry, 1:100.
The secondary antibodies used for Western blotting were anti-rabbit
immunoglobulin G (IgG) peroxidase antibody (1:10,000; whole mol-
ecule, A0545) and anti-mouse IgG peroxidase antibody (1:5000;
wholemolecule, A4416). The hERG1 inhibitor E4031was used as pre-
viously described (23) at a final concentration of 40 mM, except for
the patch-clamp experiments shown in Fig. 4A, where E4031 was
used at 2 mM.
Plasmids
To produce the peCFP-hERG1 plasmid, the full hERG1 cDNA sequence
was subcloned from pcDNA3.1(+)hERG1 into peCFP-N3 plasmid.
Before cloning, tomaintain the correct frame between eCFP and hERG1,
two nucleotides were inserted between aHind III recognition site and the
hERG1 start codon: (i) a 500-bp PCR fragment of hERG1 cDNA ampli-
fied from pcDNA3.1(+)hERG1 plasmid using the forward primer
TAAGCTTGGATGCCGGTGCGGAGG, with a Hind III recognition
site (bold) at the 5′ end of fragment and the hERG1 start codon (italics)
preceded by a mismatch of two nucleotides (underscored), and (ii) the
reverse primer GACCGCACCGACGACTCCCGGG. After denatura-
tion, the DNA fragment was amplified using Platinum PCR SuperMix
Taq polymerase (Invitrogen) for 25 cycles (denaturation for 30 s at 94°C,
annealing for 1 min at 50°C, and extension for 1 min at 72°C). After
cloning into a pCR II cloning vector (Invitrogen), the amplified fragment
was digested with Hind III and Bst XI restriction enzymes and inserted
into pcDNA3.1(+)hERG1, to substitute the first 500 bp of hERG1
cDNA. The modified hERG1 cDNA was then subcloned into peCFP-
N3 after Hind III/Bam HI double digestion. The peCFP-hERG1 func-
tionality was tested by Western blot and patch-clamp experiments.9 of 13
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 The clone pCDNAhERG1DC+RD was generated according to
Kupershmidt et al. (35). Briefly, a 315-bp PCR fragment, spanning
nucleotides 3052 to 3366 of hERG1 cDNA, was amplified from the
pCDNAhERG1 plasmid. The forward primer was GGACTCGAGCC-
CACCCCCAGCCTCCTCAACATCCC, with a Xho I recognition site
(bold) inserted at the 5′ end. The reverse primer was CTATCTAGAC-
TACGGGGGCAGCTCCTCACACGCCATG, with a stop codon TAG
(italics) and an Xba I recognition site (bold) inserted at the 3′ end of the
fragment. The amplifiedDNA, digestedwithXho I andXba I restriction
enzymes, was inserted into Xho I/Xba I–digested pCDNAhERG1 plas-
mid, substituting the whole C-terminal domain (amino acids 699 to
1159). The obtained clones were characterized by restriction pattern
analysis and sequenced to verify the conservation of reading frame.
Wild-type b1 integrin (47), b1 integrin lacking the C terminus (b1-
extra) (48), and theC terminus of b1 integrin linked to the transmembrane
and extracellular part of the interleukin-2 receptor (b1-cyto) were cloned
into the YFP Venus (YFP)–N1 vector. To generate the pYFP-N1 vector,
YFP cDNA was amplified with BamHI and Not I from the pCS2Venus
vector (49) and substituted to eGFP in the peGFP-N1 vector (Clontech).
The peCE-b1 plasmid containing the full-length b1A cDNAwas cut with
Hind III and SnaB I to obtain a fragment of around 2000 bp and ampli-
fied (SnaB 1 and BamHI) to generate a fragment of around 400 bp. The
two fragments were cloned into the pYFP-N1 plasmid cut on Hind III/
Bam HI. The fragments corresponding to the b1-extra and b1-cyto
constructs were amplified and cloned into the pYFP-N1 vector cut with
Kpn I and Eco RI.
Cell culture and transfection
Cells were routinely cultured at 37°C with 5% CO2 in either Dulbecco’s
modified Eagle’s medium (DMEM) (Euroclone) (HEK 293–ICLC,
GD25, and MDA-MB-231 cells) or RPMI (Euroclone) (HCT116 and
REH cells) supplemented with 10% fetal bovine serum (Euroclone).
HEK cells expressing wild-type hERG1were prepared as previously de-
scribed (23). To prepare the other stably transfected cell lines, transfec-
tion was carried out with Lipofectamine 2000 (Invitrogen). Selection
and further cell culture were performed in complete culture medium
supplemented with geneticin (G418, Invitrogen) at 0.8 mg/ml for
HEK cells and 2.0 mg/ml for HCT116 and MDA-MB-231 cells. For
HS-FLIM-FRET experiments, HEK cells were transiently transfected
with both peCFP-hERG1 and peYFP-b1 integrin plasmids. GD25 cells
were transiently cotransfected with the different b1 integrin–YFP
constructs and hERG1. GD25-b1-TR cells were described in (47).
Preparation of cells for FRET, immunoprecipitation, and
patch-clamp experiments
Cells were harvested by detaching them with 5 mM (10 mM for GD25
cells) EDTA in phosphate-buffered saline (PBS) and resuspended in
DMEM plus heat-inactivated BSA (250 mg/ml; Fraction V, Euroclone).
Next, cells were seeded onto dishes coated first with fibronectin (100 mg/ml
in serum-free medium, at 37°C for 1 hour) and then with BSA for 1 hour.
FRETmeasurements started 15 min after cell seeding and continued at
37°C for at least 100 min. When necessary (Fig. 2B), dishes coated with
BSA alone were also used.
RNA extraction, reverse transcription PCR, and QPCR
RNA extraction and reverse transcription were performed as previously
described (50). Amplification of KCNE1 was performed by QPCR
with 2 ml of cDNA derived from cell lines and human heart RNA
(Ambion), using a commercially available master mix (Invitrogen).Becchetti et al., Sci. Signal. 10, eaaf3236 (2017) 4 April 2017The primer sequences for KCNE1 were 5′-TCCATTGGAG-
GAAGGCATTA-3′ (forward primer) and 5′-CGCTGTGGTGTTA-
GACAGGA-3′ (reverse primer). PCR was performed as follows:
denaturation at 94°C for 2 min; 35 cycles at 94°C for 30 s, at 55°C
for 1 min, and at 72°C for 30 s; and final extension cycle at 72°C for
10 min. The same primers were used for QPCR analysis on HEK and
HCT116 cells transfected with the KCNE1 plasmid. The SYBR Green
fluorescent dye (Power SYBRGreen PCRMasterMix, Applied Biosys-
tems) method was applied. Glyceraldehyde-3-phosphate dehydrogenase
gene was used as a standard reference, as in (26). Nontransfected cell lines
were used for calibration.
Immunoprecipitation and immunoblotting
Procedures on cell lines were performed as previously described (23, 26).
Cardiac and cancer tissues were obtained from individual donors under-
going surgery. Leukemia samples were obtained from bone marrow as-
pirates of patients at the onset of the disease. Patients were treated at the
Molinette Hospital (Turin, Italy), at the Department of General Surgery
of the Careggi Hospital (Florence, Italy), and at the Department of He-
matology of the Careggi Hospital. Tissues were collected after informed
written consent and after approval of the local ethics committee. All
procedures were carried out at 4°C. Samples were homogenized in cold
protein extraction buffer (1× cell lysis buffer) and sonicated for 30 min.
For immunoprecipitation, total lysates (1.5 mg for cell line extracts and
0.5 mg for primary samples) were subjected to a preclearing step by in-
cubating them with Protein A/G Plus-Agarose for 2 hours at 4°C.
Thereafter, cell lysates were immunoprecipitated with the appropriate
antibody at the concentrations indicated in “Chemicals and antibodies.”
Coimmunoprecipitation of b1 integrin and hERG1 lysates was per-
formed with mAb-b1. Coimmunoprecipitation of hERG1 and b1 integ-
rin lysates was performed with mAb-hERG1. For both reactions,
Western blotting was performed on immunoprecipitates and total ly-
sates (input) from the same sample with polyclonal antibodies against
hERG1 or b1. To determine phosphorylation of Tyr
397 in FAK, FAK
was immunoprecipitated with a polyclonal antibody. Western blotting
was performed on immunoprecipitates and total lysates with polyclonal
antibodies against pTyr397 FAK, total FAK, or tubulin.
Densitometric analysis
Densitometric analysis was performed using ImageJ software (ImageJ
1.38, U.S. National Institutes of Health) on two different scans, after
background subtraction, from at least three different experiments.
When quantifying variations in hERG1–b1 integrin interactions, the
signal for the coimmunoprecipitated protein (for example, hERG1
when immunoprecipitating the b1 integrin, or b1 integrin when immu-
noprecipitating hERG1) was first divided by the signal of the protein
used for immunoprecipitation (for example, b1 integrin or hERG1)
and then normalized to the signal of the corresponding protein in the
total lysate (input hERG1 and input b1). The resulting value is indicated
as “hERG1/b1 integrin complex” throughout the manuscript and in the
figures. FAK phosphorylation was measured in immunoprecipitates
with FAK antibodies, first dividing the signal for Tyr397 of FAK by
the signal of the immunoprecipitated FAK and then normalizing this
value to the amount of FAK in the total lysate (input FAK).
Flow cytometry
Expression of wild-type and mutant hERG1 was assessed by a
FACSCanto flow cytometer, as in (28). Acquisition and analysis were
performed using FACSDiva software (BD Biosciences). Values are10 of 13
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 expressed as mean fluorescence intensity fold changes compared to
nontransfected HEK or MDA-MB-231 mock-transfected cells.
HS-FLIM-FRET experiments
We used a multiphoton microscope consisting of a Nikon TE2000-U
inverted opticalmicroscope, equippedwith aNikon PCM2000 confocal
laser scanning unit,modified to allow the use of an ultrafast laser source,
equipped with a dichroic short-pass filter, suitable for multiphoton
operation (650DCSPXR, Chroma Inc.). This system is made up of a
mode-locked Ti:sapphire oscillator (Mira 900 F, Coherent Inc.)
pumped by a frequency-doubled Nd:YVO4 laser system at 532 nm
and 5 W (Verdi V5, Coherent Inc.). Emission is tunable in the range
700 to 980 nm, with a typical pulse duration of 130 fs and a repetition
rate of 76MHz. The laser beam, after passing through a Faraday isolator
(to prevent a part of the laser beam returning to the laser cavity), was
directly coupled to the confocal scanning unit. The confocal head is
supplied with two output fluorescence emission channels (51). For
themeasurements, the light emitted from the sample was sent to a spec-
trograph, coupled to a fast 16-channel photon-counting photo-
multiplier, with a typical transit time spread of 150 ps (PML-16C,
Becker & Hickl GmbH). A two-photon cutoff filter (BG39, SCHOTT
GmbH)was inserted in the fluorescence path to remove unwanted back
reflection of the laser light. Acquired signals were processed by the
FLIM apparatus, which is based on time-correlated single-photon
counting and allows the measurement of the fluorescence decay curve
for each image pixel. Its core element is an SPC-830 module (Becker &
Hickl GmbH) that can measure the arrival time delays of individual
photons with respect to a synchronization pulse train, provided by
the signal of a fast photodiode (PHD-100, Becker & Hickl GmbH) that
detects a laser light reflection from the neutral density filter. Curve
fitting with exponential decay curves to the measured data and displays
of the results was performed by the software SPCImage (Becker &Hickl
GmbH).
The specificity and sensitivity of the FLIM technique to detect FRET
in cells were tested using HEK transiently cotransfected with b1 integ-
rin–eYFP and hERG1-eCFP, either as single or as double transfectants
(fig. S3). The theoretical expressions used are described in Supplemen-
taryMaterials andMethods (“Analysis ofHS-FLIM-FRETdata”). FLIM
measurements can be affected by pH, temperature, previous prolonged
exposure to radiation, and ion concentration. Spectral control is thus
essential, especially when performing FLIM experiments in living cells.
The details of our procedure are given in Supplementary Materials and
Methods (“Analysis of HS-FLIM-FRET data”) and the legends to figs.
S4 and S5.
FRET by acceptor photobleaching experiments
Weused a custom-made confocalmicroscope equippedwith a spinning
disk unit, as previously described (52) and further detailed in the Sup-
plementary Materials. FRET was detected by an increase of the donor
signal in acceptor bleaching. From the ratio of the donor fluorescent
emissions before and after acceptor photobleaching, the pixel-by-pixel
value of FRET transfer was determined. The percentage of FRET events,
which reflected the abundance of hERG1/b1 integrin complexes, was
estimated as the number of pixels for which FRET was detected in rela-
tion to the number of pixels in which the b1 integrin signal was simul-
taneously recorded. A detailed description of data acquisition and
analysis is also reported in the SupplementaryMaterials, in which flow-
charts are included for image acquisition and processing steps. Data
analysis was performed using MATLAB (MathWorks). ExperimentsBecchetti et al., Sci. Signal. 10, eaaf3236 (2017) 4 April 2017were performed on HEK cells expressing wild-type hERG1, hERG1-
R531C, or hERG1-K525C cultured for 45 min on fibronectin-coated
slides. Cells were fixed with 4% paraformaldehyde and labeled with
Alexa-conjugated mAb-hERG1 and mAb-b1. Purified mAb-hERG1
and mAb-b1 were labeled using the Alexa Fluor 488 and 546 Protein
Labeling Kits (Molecular Probes), respectively. Quantitative estimation
of labeled antibodies was determined by electrophoresis in agarose gel
and Coomassie Brilliant Blue staining.
Patch-clamp recording
IhERG1 was recorded in the whole-cell configuration of the patch-clamp
technique, at room temperature (~25°C), with aMultiClamp 700A am-
plifier (Molecular Devices), as previously described (53). E4031 was
used at 2 mM. Background currents and leakage were measured in
the presence of E4031 and subtracted from the total current.Unless oth-
erwise indicated, [K+]o was 5 mM. hERG1-K525C currents were re-
corded in 2 mM extracellular [K+]. The activation curves for hERG1,
hERG1D2-370, hERG1DC+RD, and hERG1-G628S were determined
frompeak tail currents (Itail) at−120mV (for 1.1 s), after 15-s conditioning
potentials from 0 to −70mV (10-mV steps, spaced 4 s apart). The holding
potential (VH) was 0 mV. The activation curves for wild-type hERG1,
hERG1-K525C, and hERG1-R531C were obtained after a stimulation
protocol similar to that used by Zhang et al. (39). From a negative VH
(−80 to−120mV),we applied 1-s test voltages (10-mV increments) every
15 s. Test voltages (Vt) varied from−60 to +40mV (hERG1), from−70 to
+50 mV (hERG1-K525C), and from −30 to +70 mV (hERG1-R531C).
Itail was elicited by repolarization to −50 mV (−80 mV for hERG1-
K525C). Thepeak Itail obtainedat eachVt wasnormalized to themaximum
Itail (Imax). The relation between Itail/Imax and Vt was fit to a Boltzmann
function with OriginPro 2015 (OriginLab) software.
In vivo experiments
Experiments were performed at the Animal House of the University of
Florence (CESAL). Mice were housed in filter-top cages with a 12-hour
dark-light cycle and had unlimited access to food andwater. Procedures
were conducted according to the laws for experiments on live animals
(Directive 2010/63/EU) and approved by the ItalianMinistry of Health
(1279/2015-PR).
For subcutaneous xenografts, female nude mice (Harlan Labora-
tories) aged 5 to 6 weeks were injected subcutaneously in either flanks
with 2 × 106 cells, resuspended in 50 ml of ice-cold PBS and gentlymixed
with the same volume of ice-cold Matrigel. The following human cell
lines were used: HEK-hERG1, HEK-hERG1-G628S, HEK-hERG1-
R531C, andHEK-hERG1-K525C. Each experimental group comprised
three mice. One group of mice injected with HEK-hERG1 was treated
daily with E4031 (20 mg/kg), injected into the peritoneum, for 2 weeks,
starting the day after inoculum. The volume of tumormasses measured
at the sacrifice (6weeks after inoculation)was calculated by applying the
ellipsoid equation.
For breast orthotopic xenografts, female SCIDmice (Harlan Labora-
tories) aged 6 weeks were injected in both fourth mammary fat pads
(five mice per group), with different cell types (2 × 106 cells per mouse):
MDA-MB-231–hERG1, MDA-MB-231–hERG1-R531C, or MDA-
MB-231–hERG1-K525C. After injection, mice were monitored daily
to ensure that they did not show any signs of suffering or disease (such
as weight loss, abdominal distension, or impaired movement). Five
weeks after injection, mice were euthanized, and tumor masses and tis-
sues were collected and processed for histological analysis. The volume
of tumormasses at the sacrifice was calculated by applying the following11 of 13
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 expression: 0.52 × lmin
2 × lmax, where lmin and lmax are theminimumand
maximummeasured length of the tumor mass, respectively. Hematox-
ylin and eosin staining and immunostaining of lung metastases were
performed as in (26). To quantify the metastatic burden, images were
acquired on a LeicaDM4000Bmicroscopewith a LeicaDFC320 camera
using Leica QWin software (Leica Microsystems). The percentage of
metastatic areas permicroscopic fieldwas determined as in (54). At least
three fields per mouse lung and both lungs were examined.
Statistical analysis
Unless otherwise indicated, data are given asmean values ± SEM,withn
indicating the number of independent experiments. Statistical compar-
isons were performed with OriginPro 2015 and SAS 9.2 (SAS Institute)
software. The normality of data distribution was checked with K-S test.
In the case of normal distributions, each data set was first checked for
variance homogeneity, using the F test for equality of two variances
and the Brown-Forsythe test for multiple comparisons. For data with
unequal variances, the Welch correction was applied. For comparisons
between two groups of data, we used the Student’s t test. A two-sample
K-S test was performed to test whether two underlying probability distri-
butions differed. For multiple comparisons, one-way ANOVA followed
by Bonferroni’s post hoc test was performed to derive P values. As re-
ported in the figure legends, in case of unequal variances, ANOVA was
followed by the Hochberg’s GT2 post hoc method. In the case of non-
normal distributions, nonparametric Kruskal-Wallis ANOVA followed
by DSCF’s post hoc method was applied. The relevant P values are re-
ported in the figure panels and legends.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/10/473/eaaf3236/DC1
Materials and Methods
Fig. S1. Characterization of HEK 293 and HCT116 cells transfected with KCNE1.
Fig. S2. Coimmunoprecipitation of HEK-hERG1 cells seeded on fibronectin.
Fig. S3. Characterization of HEK CFPhERG1+b1YFP cells.
Fig. S4. Fluorescence decay of a donor control sample.
Fig. S5. Control experiments to validate FRET results.
Fig. S6. Protocol for image acquisition of HEK 293 cells.
Fig. S7. Background correction and FRET map calculation.
Fig. S8. FRET efficiency as a function of the ratio of donor to acceptor.
Fig. S9. Lymph node metastases in mice orthotopically injected with MDA-MB-231–hERG1 and
MDA-MB-231–hERG1-R531C cells.
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